# Managed Access Programs for ABL001, Asciminib

> **NCT04360005** · — · AVAILABLE · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Chronic Myeloid Leukemia in Chronic Phase

## Interventions

- **DRUG:** Asciminib

## Key facts

- **NCT ID:** NCT04360005
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04360005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04360005, "Managed Access Programs for ABL001, Asciminib". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04360005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*